机构

• 上海药物研究所 [12]

采集方式

• OAI收割 [12]

内容类型

• 期刊论文 [12]

发表日期

• 2021 [12]

学科主题

筛选

浏览/检索结果: 共12条，第1-10条 帮助 限定条件 发表日期：2021    专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序题名升序题名降序作者升序作者降序发表日期升序发表日期降序 Improved structural annotation of triterpene metabolites of traditional Chinese medicine in vivo based on quantitative structure-retention relationships combined with characteristic ions: Alismatis Rhizoma as an example 期刊论文  OAI收割 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2021, 卷号: 1187, 页码: 10 作者:  Yan, Pan;  Wang, Lu;  Li, Sen;  Liu, Xuechen;  Sun, Yi   |  收藏  |  浏览/下载：19/0  |  提交时间：2022/06/15 Alismatis Rhizoma  Metabolites  Quantitative structure-retention relationship  Characteristic ions   Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein 期刊论文  OAI收割 ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 页码: 11 作者:  Fan, Shijie;  Yue, Liyan;  Wan, Wei;  Zhang, Yuanyuan;  Zhang, Bidong   |  收藏  |  浏览/下载：98/0  |  提交时间：2021/12/16 covalent modification  probes  proteome  LC3  post-translational modification   Discovery of a Potential Liver Fibrosis Inhibitor from a Mushroom Endophytic Fungus by Genome Mining of a Silent Biosynthetic Gene Cluster 期刊论文  OAI收割 JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2021, 卷号: 69, 期号: 38, 页码: 11303-11310 作者:  Cheng, Jin-Tao;  Wang, Han-Min;  Yu, Jia-Hui;  Sun, Chen-Fan;  Cao, Fei   |  收藏  |  浏览/下载：24/0  |  提交时间：2021/12/01 fungus  Calcarisporium arbuscula  natural product  gene cluster activation  liver fibrosis   P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13 作者:  Zhou, Xiao-ru;  Li, Xiao;  Liao, Li-ping;  Han, Jie;  Huang, Jing   |  收藏  |  浏览/下载：49/0  |  提交时间：2021/06/11 mantle cell lymphoma  idelalisib  drug resistance  P300  CBP  synergistic drug action  PI3Kδ  epigenetics   P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K delta inhibitor idelalisib 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 13 作者:  Zhou, Xiao-ru;  Li, Xiao;  Liao, Li-ping;  Han, Jie;  Huang, Jing   |  收藏  |  浏览/下载：54/0  |  提交时间：2021/06/11 mantle cell lymphoma  idelalisib  drug resistance  P300  CBP  synergistic drug action  PI3Kδ  epigenetics   Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Jiang, Kai-long;  Tong, Le-xian;  Wang, Tao;  Wang, Han-lin;  Hu, Xiao-bei   |  收藏  |  浏览/下载：49/0  |  提交时间：2021/05/24 CHK1 inhibitors  PY34  drug sensitivity  c-Myc  hematologic malignancies   A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia 期刊论文  OAI收割 Alzheimer's Research & Therapy, 2021, 卷号: 13, 期号: 1 作者:  Xiao,Shifu;  Chan,Piu;  Wang,Tao;  Hong,Zhen;  Wang,Shuzhen   |  收藏  |  浏览/下载：86/0  |  提交时间：2021/05/24 Sodium oligomannate  Efficacy  Safety  Alzheimer’s disease  Clinical trial   Discovery of New alpha-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation 期刊论文  OAI收割 FRONTIERS IN CHEMISTRY, 2021, 卷号: 9, 页码: 9 作者:  Liu, Shan-Kui;  Hao, Haifang;  Bian, Yuan;  Ge, Yong-Xi;  Lu, Shengyuan   |  收藏  |  浏览/下载：33/0  |  提交时间：2021/05/24 α  -glycosidase  virtual screening  cytotoxicity  type 2 diabetes  molecular docking   Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2021, 卷号: 64, 期号: 4, 页码: 1844-1855 作者:  Zhou, Yu;  Fu, Yan;  Yin, Wanchao;  Li, Jian;  Wang, Wei   |  收藏  |  浏览/下载：23/0  |  提交时间：2021/05/24 Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia 期刊论文  OAI收割 CHEMMEDCHEM, 2021, 页码: 12 作者:  Jin, Tingting;  Wang, Peipei;  Long, Xiubing;  Jiang, Kailong;  Song, Pinrao   |  收藏  |  浏览/下载：126/0  |  提交时间：2021/05/24 CHK1 inhibitor  diaminopyrimidine  DNA damage response  oral bioavailability